We speak with Prof Philip Poortmans, President of ESTRO and co-author on an editorial in the latest issue of Clinical Oncology, regarding the role of IMN Radiotherapy in early breast cancer. He discusses the background and evidence for this treatment and offers insights into the design and results from his recent EORTC trial.